MannKind (MNKD) Competitors

Ligand Pharmaceuticals (NASDAQ:LGND) and MannKind (NASDAQ:MNKD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Which has stronger earnings & valuation, LGND or MNKD?

MannKind has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$181.49M	13.49	-$4.03M	-$7.12	-17.83
MannKind	$285.50M	4.29	$27.59M	$0.10	40.30

Do analysts prefer LGND or MNKD?

Ligand Pharmaceuticals presently has a consensus price target of $147.17, indicating a potential upside of 15.95%. MannKind has a consensus price target of $10.33, indicating a potential upside of 156.41%. Given MannKind's stronger consensus rating and higher possible upside, analysts clearly believe MannKind is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
MannKind	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.29

Does the media favor LGND or MNKD?

In the previous week, Ligand Pharmaceuticals had 12 more articles in the media than MannKind. MarketBeat recorded 14 mentions for Ligand Pharmaceuticals and 2 mentions for MannKind. MannKind's average media sentiment score of 0.90 beat Ligand Pharmaceuticals' score of 0.76 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, LGND or MNKD?

Ligand Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, MannKind has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.

Is LGND or MNKD more profitable?

MannKind has a net margin of 10.12% compared to Ligand Pharmaceuticals' net margin of -73.07%. Ligand Pharmaceuticals' return on equity of -7.83% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	-73.07%	-7.83%	-6.92%
MannKind	10.12%	-32.41%	10.85%

Do institutionals & insiders have more ownership in LGND or MNKD?

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 7.0% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 3.0% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

MannKind beats Ligand Pharmaceuticals on 11 of the 17 factors compared between the two stocks.